Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention.

Background and Purpose- Despite treatment with oral anticoagulants, patients with nonvalvular atrial fibrillation (AF) may experience ischemic cerebrovascular events. The aims of this case-control study in patients with AF were to identify the pathogenesis of and the risk factors for cerebrovascular ischemic events occurring during non-vitamin K antagonist oral anticoagulants (NOACs) therapy for stroke prevention. Methods- Cases were consecutive patients with AF who had acute cerebrovascular ischemic events during NOAC treatment. Controls were consecutive patients with AF who did not have cerebrovascular events during NOACs treatment. Results- Overall, 713 cases (641 ischemic strokes and 72 transient ischemic attacks; median age, 80.0 years; interquartile range, 12; median National Institutes of Health Stroke Scale on admission, 6.0; interquartile range, 10) and 700 controls (median age, 72.0 years; interquartile range, 8) were included in the study. Recurrent stroke was classified as cardioembolic in 455 cases (63.9%) according to the A-S-C-O-D (A, atherosclerosis; S, small vessel disease; C, cardiac pathology; O, other causes; D, dissection) classification. On multivariable analysis, off-label low dose of NOACs (odds ratio [OR], 3.18; 95% CI, 1.95-5.85), atrial enlargement (OR, 6.64; 95% CI, 4.63-9.52), hyperlipidemia (OR, 2.40; 95% CI, 1.83-3.16), and CHA2DS2-VASc score (OR, 1.72 for each point increase; 95% CI, 1.58-1.88) were associated with ischemic events. Among the CHA2DS2-VASc components, age was older and presence of diabetes mellitus, congestive heart failure, and history of stroke or transient ischemic attack more common in patients who had acute cerebrovascular ischemic events. Paroxysmal AF was inversely associated with ischemic events (OR, 0.45; 95% CI, 0.33-0.61). Conclusions- In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not exclusively of cardioembolic pathogenesis, off-label low dose, atrial enlargement, hyperlipidemia, and high CHA2DS2-VASc score were associated with increased risk of cerebrovascular events.

[1]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[2]  A. Fox,et al.  Accuracy and prognostic consequences of ultrasonography in identifying severe carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. , 1995, Stroke.

[3]  A. Alexandrov,et al.  Correlation of peak systolic velocity and angiographic measurement of carotid stenosis revisited. , 1997, Stroke.

[4]  H. A. Smith,et al.  A standardized method for measuring intracranial arterial stenosis. , 2000, AJNR. American journal of neuroradiology.

[5]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[6]  Richard Sutton,et al.  International consensus on nomenclature and classification of atrial fibrillation: A collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. , 2003, Journal of cardiovascular electrophysiology.

[7]  S. Lévy,et al.  International Consensus on Nomenclature and Classification of Atrial Fibrillation: A Collaborative Project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology , 2003, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[9]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[10]  M. Hennerici,et al.  New Approach to Stroke Subtyping: The A-S-C-O (Phenotypic) Classification of Stroke , 2009, Cerebrovascular Diseases.

[11]  W. Ageno,et al.  Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. , 2010, Atherosclerosis.

[12]  P. Colonna,et al.  Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC). , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[13]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[14]  D. Parra,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011 .

[15]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[16]  M. Hennerici,et al.  The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping) , 2013, Cerebrovascular Diseases.

[17]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[18]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[19]  A. Alexandrov,et al.  Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis , 2016, Therapeutic Advances in Neurological Disorders.

[20]  D. Singer,et al.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes , 2016 .

[21]  P. Michel,et al.  Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials , 2017, International journal of stroke : official journal of the International Stroke Society.

[22]  U. Ziemann,et al.  Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions , 2017, Stroke.

[23]  D. Singer,et al.  Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II) , 2018, Journal of the American Heart Association.

[24]  A. Tosetto,et al.  Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme , 2018, Journal of thrombosis and haemostasis : JTH.